



AMERICAN
UNIVERSITY
OF BEIRUT



NAEF K. BASILE
CANCER INSTITUTE

BEST OF ASCO®
OFFICIALLY LICENSED

THE 19TH BEST OF ASCO24

 **July 12 - 13, 2024** |  **Beirut, Lebanon**

Hybrid Meeting

Halim & Aida Daniel ACC Building
American University of Beirut Medical Center (AUBMC)

Best of ASCO Lebanon Chair:
Nagi S. El Saghir, MD, FACP, FASCO

Organized by AUBMC

Licensed by ASCO

In collaboration with: King Hussein Cancer Center (KHCC), Lebanese Society of Medical Oncology (LSMO),
and Africa Middle-East Cancer-Research Intergroup (AMCI).



WELCOME ADDRESS FROM THE PRESIDENT



Dear Colleagues and Friends,

It is my great pleasure to invite you again to our **Annual Best of ASCO Lebanon Meeting** that we hold this year in HYBRID format. Speakers and Attendees in Lebanon will be in-person, speakers and attendees from overseas will be virtual.

Best of ASCO24 is licensed by the American Society of Clinical Oncology (ASCO), and we will hold it Lebanon on **July 12 - 13, 2024** in HYBRID from the Daniel ACC Building Conference Rooms at the American University of Beirut Medical Center (AUBMC).

Best of ASCO 2024 is organized by the Division of Hematology Oncology of the Department of Internal Medicine and the Naef K. Basile Cancer Institute (NKBCI) of the American University of Beirut Medical Center (AUBMC), in collaboration with King Hussein Cancer Center (KHCC), Lebanese Society of Medical Oncology (LSMO) and Africa Middle-East Cancer-Research Intergroup (AMCI).

Great advances in cancer research, practice-changing clinical trials and advances in patient management presented and discussed at ASCO24 in Chicago, IL, USA will be presented and discussed at Best of ASCO Lebanon. Presenters, Chairs, Discussants, and Attendees will have ample time for discussions and take-home messages.

Please note that Advance Registration is free and mandatory. Deadline for registration is July 11, 2024. All abstracts selected by Best of ASCO are enclosed in this brochure. Looking forward to a great meeting in Beirut, LB!

Nagi S. El Saghir, MD, FACP, FASCO

Professor & Head of Hematology-Oncology, American University of Beirut Medical Center

Chair, Best of ASCO Lebanon

ns23@aub.edu.lb @NagiSaghir

IMPORTANT INFORMATION

ORGANIZED BY:

Division of Hematology Oncology and the Naef Basile Cancer Institute (NKBCI) of the American University of Beirut Medical Center (AUBMC)

IN COLLABORATION WITH:

King Hussein Cancer Cancer (KHCC), Lebanese Society of Medical Oncology (LSMO) and Africa Middle East Cancer Intergroup (AMCI)

LICENSED BY:

The American Society of Clinical Oncology

BEST OF ASCO LEBANON CHAIR:

Nagi S. El Saghir, MD, FACP, FASCO

BEST OF ASCO LEBANON PLANNING COMMITTEE:

Nagi S. El Saghir, MD, FACP, FASCO (Chair), Hikmat AbdelRazek, MD (Co-Chair), Hiba Moukadem, MD (Secretary), Reem Abdallah, MD, Ghassan Abou-Alfa, MD, MBA, Iman Abou Dalle, MD, Reem Abdallah, MD, Hamdy Azim, MD, Albert El-Hajj, Fadi El Karak, Fadi Farhat, Joseph Makdessi, MD, Marwan Ghosn, MD



GUEST SPEAKERS



FRIDAY, JULY 12, 2024

PROGRAM

10:00 - 10:30	<p>Welcome Address Opening Ceremony</p> <p>Nagi S. El Saghir, MD, FACP, FASCO Chair, Best of ASCO Lebanon</p> <p>Hikmat AbdelRazek, MD Chief Medical Officer, KHCC</p> <p>Ali Taher, MD Director, NKBCI, AUBMC</p>	<p>TBA</p> <p>TBA</p> <p>TBA</p>
10:30 - 11:30	<p>SESSION 1: BREAST CANCER - METASTATIC</p> <p>Moderators:</p>	
	<p>Abstract: LBA1007 Trastuzumab & Pertuzumab in Combination with Eribulin Mesylate or a Taxane as First-line Chemotherapeutic Treatment for HER2-positive, Locally Advanced or Metastatic Breast Cancer: Results of a Multicenter, Randomized, Non-Inferiority Phase 3 Trial in Japan (JBCRG-M06/EMERALD)</p> <p>Toshinari Yamashita, MD</p>	<p>Ahmad Awada, MD</p>
	<p>Abstract: LBA1002 Palbociclib Plus Exemestane with GnRH Agonist vs Capecitabine in Premenopausal Patients with HR+/HER2- Metastatic Breast Cancer: Updated Survival Results of the Randomized Phase 2 Study Young-PEARL Yeon Hee Park, MD</p>	<p>Sanaa El Sukhun, MD</p>
	<p>Abstract: LBA1001 Abemaciclib Plus Fulvestrant vs Fulvestrant Alone for HR+, HER2- Advanced Breast Cancer Following Progression on a Prior CDK4/6 Inhibitor Plus Endocrine Therapy: Primary Outcome of the Phase 3 Post MONARCH Trial Kevin Kalinsky, MD</p>	<p>Nagi S. El Saghir, MD</p>
	<p>Abstract: LBA1000 Trastuzumab Deruxtecan (T-DXd) vs Physician's Choice of Chemotherapy (TPC) in Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) with Prior Endocrine Therapy (ET): Primary Results from DESTINY-Breast06 (DB-06) Giuseppe Curigliano, MD</p>	<p>Giuseppe Curigliano, MD, PhD</p>

11:30 - 12:00	 Coffee Break
12:00 - 12:30	<div>SESSION 2: CNS TUMORS & PEDIATRIC Moderators:</div> <div><div><i>Abstract: LBA2000</i> N2M2/NOA-20: Phase I/IIa Umbrella Trial of Molecularly Matched Targeted Therapies plus Radiotherapy in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation Wolfgang Wick, MD</div><div><i>Abstract: LBA10000</i> Efficacy & Safety of Entrectinib in Children with Extracranial Solid or Primary Central Nervous System (CNS) Tumors Harboring NTRK or ROS1 Fusions Ami V. Desai, MD</div></div>
12:30 - 13:00	<div>Pfizer Symposium Stay Strong Against ALK+ Locally Advanced or Metastatic NSCLC with 1 L Lorbrena</div> <div>Arafat Tfayli, MD</div>
13:00 - 14:00	 Lunch Break



FRIDAY, JULY 12, 2024

PROGRAM

14:00 - 15:15

SESSION 3: GASTROINTESTINAL CANCER-COLORECTAL, PANCREATIC & HEPATOBIILIARY

Moderators:

Abstract: LBA1 | Prospective Randomized Multicenter Phase III Trial Comparing Perioperative Chemotherapy (FLOT Protocol) to Neoadjuvant Chemoradiation (CROSS Protocol) in Patients with Adenocarcinoma of the Esophagus (ESOPEC Trial) | **Jens Hoeppe**, MD

● **Ali Shamseddine, MD**

Abstract: LBA4005 | NRG Oncology/RTOG 0848: Results after Adjuvant Chemotherapy +/- Chemoradiation for Patients with Resected Periapillary Pancreatic Adenocarcinoma (PA) | **Ross Abrams**, MD

● **Eileen O'Reilly, MD**

Abstract: LBA4003 | A Randomized Phase II Study of Gemcitabine & Nab-paclitaxel Compared with 5-Fluorouracil, Leucovorin, & Liposomal Irinotecan in Older Patients with Treatment-Naïve Metastatic Pancreatic Cancer (GIANT): ECOG-ACRIN EA2186 | **Efrat Dotan**, MD

● **Eileen O'Reilly, MD**

Abstract: LBA4008 | Nivolumab (NIVO) Plus Ipilimumab (IPI) vs Lenvatinib (LEN) or Sorafenib (SOR) as First-Line Treatment for Unresectable Hepatocellular Carcinoma (uHCC): First Results from CheckMate 9DW | **Peter Galle**, MD

● **Ghassan Abou-Alfa, MD**

Abstract: LBA108 | Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer: Overall Survival & Updated 5-year Results from the Randomized DYNAMIC Trial. | **Jeanne Tie**, MD

● **Iman El-Dika, MD**

Abstract: LBA3503 | Nivolumab (NIVO) plus Ipilimumab (IPI) vs Chemotherapy (Chemo) as First-line (1L) Treatment for Microsatellite Instability-High/Mismatch Repair-Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC): Expanded Efficacy Analysis from CheckMate 8HW. | **Heinz-Josef Lenz**, MD

● **Marwan Al-Hajeili, MD**



FRIDAY, JULY 12, 2024

PROGRAM

15:15 - 16:45

SESSION 5: BREAST CANCER - LOCAL/REGIONAL

Moderators:

Abstract: LBA500 | A-brave Trial: A Phase III Randomized Trial with Avelumab in Early Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy or at High Risk after Primary Surgery & Adjuvant Chemotherapy | **Pier Franco Conte, MD**

● **Meteb Al-Foheidi, MD**

Abstract: LBA505 | Correlation of Serum Anti-müllerian Hormone (Amh) Levels on Identification of Premenopausal Patients (Pts) with Hormone Receptor Positive (Hr+), Her2-Negative, Node-Positive Breast Cancer Most Likely to Benefit from Adjuvant Chemotherapy in Swog S1007 (Rxponder) | **Kevin Kalinsky, MD**

● **Etienne Brain, MD**

Abstract: LBA502 | A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Anthracyclines Followed by Taxane Versus Anthracyclines Followed by Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patients with Early Triple-negative Breast Cancer: Korean Cancer Study Group Br 15-1 Pearly Trial
Joohyuk Sohn, MD

● **Hamdy Abdel Azim, MD**

Abstract: LBA10503 | Clinical Behavior of Breast Cancer in Young BRCA Carriers & Prognostic Impact of the Timing Of Genetic Testing: Results from an International Cohort Study | **Matteo Lambertini, MD**

● **Hikmat Abdel Razek, MD**

Abstract: LBA1021 | TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase 2 Study of Olaparib Monotherapy in Patients (pts) with Metastatic Breast Cancer (MBC) with Germline (g) Mutations in PALB2 or Somatic (s) Mutations in BRCA1 or BRCA2 | **Nadine Tung, MD**

● **Ahmad Awada, MD**

Abstract: LBA507 | Prognostic Utility of Ctdna Detection in the Monarche Trial of Adjuvant Abemaciclib Plus Endocrine Therapy (Et) in Hr+, Her2-, Node-Positive, High-Risk Early Breast Cancer (Ebc)
Sherene Loi, MD

● **Nuhad Ibrahim, MD**

Abstract: LBA10512 | Real-world Cancer Care Utilization Among Patients with Breast Cancer with Germline Variants of Uncertain Significance. | **Allison W. Kurian, MD**

● **Nada Assaf, MD**



FRIDAY, JULY 12, 2024

PROGRAM

16:45 - 17:00



Coffee Break

17:00 - 18:30

SESSION 4: LUNG CANCER-NON-SMALL CELL LOCAL-REGIONAL/SMALL CELL/OTHER THORACIC CANCERS | HEAD & NECK

Moderators:

Abstract: LBA4 | Osimertinib (Osi) after Definitive Chemoradiotherapy (CRT) in Patients (pts) with Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study | **Suresh Ramalingam, MD**

● Suresh Ramalingam, MD

Abstract: LBA8503 | Lorlatinib vs Crizotinib in Treatment-Naïve Patients with Advanced ALK+ Non-Small Cell Lung Cancer: 5-year Progression-Free Survival & Safety from the CROWN Study | **Benjamin Solomon, MD**

● Suresh Ramalingam, MD

Abstract: LBA5 | ADRIATIC: Durvalumab (D) as Consolidation Treatment (tx) for Patients (pts) with Limited-stage Small-Cell Lung Cancer (LS-SCLC) | **David Spigel, MD**

● Fadlo Khuri, MD

Abstract: LBA8002 | BEAT-meso: A Randomized Phase III Study of Bevacizumab (B) & Standard Chemotherapy (C) with or without Atezolizumab (A), as First-line Treatment (TX) for Advanced Pleural Mesothelioma (PM)-Results from the ETOP 13-18 Trial | **Sanjay Popat, MD**

● Fadlo Khuri, MD

Abstract: LBA8506 | NRG-LU002: Randomized Phase II/III Trial of Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-small Cell Lung Cancer (NSCLC) | **Puneeth Iyengar, MD**

● Arafat Tfayli, MD

Abstract: LBA8509 | KRYSTAL-12: Phase 3 Study of Adagrasib Versus Docetaxel in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring a KRASG12C Mutation | **Tony Mok, MD**

● Taher Abou Hajleh, MD

Abstract: LBA6006 | Phase III Randomized Trial of Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Head & Neck Oropharyngeal Carcinoma (OPC). | **Steven Frank, MD**

● Bassem Youssef, MD



SATURDAY, JULY 13, 2024

PROGRAM

10:00 - 11:15

SESSION 1: HEMATOLOGIC MALIGNANCIES-PLASMA CELL DYSCRASIAS

Moderators: Iman Abou Dalle, MD - Nour Moukalled, MD - Abir Ahmadieh, MD

Abstract: LBA7500 | Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide & Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)
Thierry Facon, MD

● **Thierry Facon, MD**

Abstract: LBA105 | Results from the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin plus Pomalidomide & Dexamethasone (BPd) vs Pomalidomide plus Bortezomib & Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM) | **Suzanne Trudel, MD**

● **Claudio Cerchione, MD**

Abstract: LBA7504 | Ciltacabtagene Autoleucel vs Standard of Care in Patients with Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis | **Luciano J. Costa, MD**

● **Claudio Cerchione, MD**



SATURDAY, JULY 13, 2024

PROGRAM

HEMATOLOGIC MALIGNANCIES-LYMPHOMA & CHRONIC LYMPHOCYTIC LEUKEMIA

Abstract: LBA7000 | Tolerability & Efficacy of BrECADD Versus BEACOPP in Advanced Stage Classical Hodgkin Lymphoma: GHSG HD21, a Randomized Study. | **Peter Borchmann, MD**

● **Ali Bazarbachi, MD**

Abstract: LBA7007 | Efficacy & Safety of Ibrutinib plus Venetoclax in Patients with Mantle Cell Lymphoma (MCL) & TP53 Mutations in the SYMPATICO Study. | **Michael Wang, MD**

● **Ali Bazarbachi, MD**

HEMATOLOGIC MALIGNANCIES-LEUKEMIA, MYELOYDYSPLASTIC SYNDROMES, & ALLOTRANSPLANT

Abstract: LBA6500 | ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS TKIs) in Newly Diagnosed Patients (pts) with Chronic Myeloid Leukemia (CML): Primary Results. | **Timothy Hughes, MD**

● **Colette Hanna, MD**

11:15 - 11:45



Coffee Break

11:45 - 12:30

SESSION 2: GYNECOLOGIC CANCERS

Moderators:

Abstract: LBA5504 | Adjuvant Chemotherapy Following Concurrent Chemoradiation (CRT) in Patients with High-risk Early-Stage Cervical Carcinoma Following Radical Hysterectomy: Results of NRG Oncology/RTOG 0724/GOG-0724 | **Anuja Jhingran, MD**

● David Atallah, MD

Abstract: LBA5506 | Phase II Randomized Multi-Centre Study of Neoadjuvant Olaparib in Patients with Platinum Sensitive Relapsed High Grade Serous Ovarian Cancer: The NEO Trial | **Stephanie Lheureux, MD**

● Muhieddine Seoud, MD

12:30 - 13:30

Abstract: LBA5511 | A phase II Study of Fulvestrant & Abemaciclib in Hormone Receptor Positive Advanced or Recurrent Endometrial Cancer | **Angela Green, MD**

● Hiba Moukadem, MD



Lunch Break



SATURDAY, JULY 13, 2024

PROGRAM

13:30 - 15:00

SESSION 3: GU CANCERS: KIDNEY CANCER, UROTHELIAL CANCER

Moderators:

Abstract: LBA4509 | Characterization of Complete Responders to Nivolumab + Gemcitabine-cisplatin vs Gemcitabine-Cisplatin Alone & Patients with Lymph Node-only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial | **Matt Galsky, MD**

● **Hassan Ghazal, MD**

Abstract: LBA4508 | Avelumab + Axitinib vs Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (aRCC): Final Overall Survival (OS) Analysis from the JAVELIN Renal 101 Phase 3 Trial | **Robert Motzer, MD**

● **Joseph Makdessi, MD**

Abstract: LBA4502 | Patient-reported Outcomes (PROs) from a Randomized, Phase 3 Trial of Enfortumab Vedotin Plus Pembrolizumab (EV+P) Versus Platinum-Based Chemotherapy (PBC) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC) | **Shilpa Gupta, MD**

● **Sally Tamraz, MD**

15:00 - 15:45

SESSION 4: GU CANCERS: PROSTATE/TESTICULAR/PENILE CANCERS

Moderators:

Abstract: LBA5011 | ARV-766, a Proteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degradar in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results of a Phase 1/2 Study | **Daniel P. Petrylak**

● **Deborah Mukherji, MD**

Abstract: LBA5003 | Health-Related Quality of Life & Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore) | **Karim Fizazi, MD**

● **Mohammad Haidar, MD**



SATURDAY, JULY 13, 2024

PROGRAM

15:45 - 16:15

SESSION 5: MELANOMA & SKIN CANCERS

Moderators:

Abstract: LBA2 | Neoadjuvant Nivolumab Plus Ipilimumab Versus Adjuvant Nivolumab in Macroscopic, Resectable Stage III Melanoma: The Phase 3 NADINA Trial | **Christian Blank, MD**

● **Hussein Tawbi, MD**

Abstract: LBA9500 | Long-Term Follow up for Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study | **Axel Hauschild, MD**

● **Firas Kreidieh, MD**

16:15

Closing Remarks: **Nagi S. El Saghir, MD, FASCO, FACP**



Organized by:



LEBANON

4th Floor, Qubic Center
Daoud Ammoun Street
Horsh Tabet - Sin El Fil
P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Mobile: +961 71 103123

UAE

DMCC Business Centre
Almas Tower
Jumeirah Lakes
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +971 50 9110475

KUWAIT

Mezzanine floor,
Aliya Complex
Salem Al Mubarak St
Block 2, Salmiya - Kuwait
Tel: +965 6556 7669

infomed@infomedweb.com | www.infomedweb.com

